Minimum Bio is a biotech company that aims to revolutionize drug discovery by accelerating early phase R&D in the pharmaceutical sector, saving years and hundreds of millions of dollars in drug development costs. Minimum Bio has developed a versatile, high throughput discovery technology with broad applications in the development of new therapeutic products and the repositioning of existing drugs. The company’s expertise and know-how is based on its phage display technology platform that permits it to rapidly identify proteins that bind to bioactive molecules of interest. The company has repurposed antibody phage display for drug target discovery and believes that this platform is a powerful method that can also be used to identify protein targets of small molecules, biologics, and other bioactive compounds, and has significant advantages over conventional and mass spectrometry-based approaches. Advantages include increased speed, less background, and less bias toward common, high-abundance targets.
Something looks off?